Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6576795

CC(C)(C)NN.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
TSHR P16473 2/20 0.38
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
CA2 P00918 1/20 0.33
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
MAPK1 P28482 1/20 0.32
THPO P40225 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL31050235 0.82 CA2 (0.36) ALDH1A1TSHRNOS1NOS2CA2
Trifluoroacetic Acid SCHEMBL28224030 0.82 CA2 (0.36) ALDH1A1TSHRNOS1NOS2CA2
Pivalate SCHEMBL10759742 0.82 ALDH1A1 (0.42) ALDH1A1TSHRKDM4ELMNACYP1A2
Trifluoroacetic Acid SCHEMBL9060237 0.80 ALDH1A1 (0.40) ALDH1A1TSHRNOS1NOS2CA2
Acetic Acid SCHEMBL7438398 0.79 FFAR3 (0.47) ALDH1A1TSHRCA2KDM4ELMNA
Oxalic Acid SCHEMBL919497 0.79 ALOX15 (0.40) ALDH1A1TSHRCA2KDM4ELMNA
Trifluoroacetic Acid SCHEMBL2267588 0.79 ALDH1A1 (0.44) ALDH1A1TSHRNOS1NOS2CA2
Oxalic Acid SCHEMBL10737273 0.79 ALOX15 (0.40) ALDH1A1TSHRCA2KDM4ELMNA
Trifluoroacetic Acid SCHEMBL1731636 0.78
Trifluoroacetic Acid SCHEMBL29615579 0.78 ALDH1A1 (0.41) ALDH1A1TSHRNOS1NOS2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1090019-B1 ADENOSINE DERIVATIVES GLAXO GROUP LTD (GB) 2004-09-29 EP disclosed
EP-1447407-A1 Adenosine derivatives GLAXO GROUP LIMITED (GB) 2004-08-18 EP disclosed
US-6677316-B2 TREATING ISCHEMIA, CARDIOVASCULAR DISORDERS, STROKE, PAIN, NERVOUS SYSTEM DISORDERS OR SLEEP APNEA; ADENOSINE A1 RECEPTOR AGONIST; 2-(3-(TERT-BUTYL)-1,2,4-OXADIAZOL-5-YL)-5-(6-(ISOBUTYLAMINO)-9H-PURIN-9-YL) TETRAHYDROFURAN-3,4-DIOL SMITHKLINE BEECHAM CORPORATION 2004-01-13 US disclosed
US-20030096788-A1 Adenosine derivatives GLAXO WELLCOME INC. 2003-05-22 US disclosed
US-6492348-B1 Adenosine derivatives SMITHKLINE BEECHAM CORPORATION 2002-12-10 US disclosed
EP-1090019-A1 ADENOSINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-04-11 EP disclosed
WO-1999067262-A1 ADENOSINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096788-A1 Adenosine derivatives ADORA3, ADORA2A, ADORA1 ALDH1A1 239/4885TSHR 627/4885NOS1 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.